What is the clinical evidence from this study?

Study design: Other. Population: Cancer (preclinical). Intervention: Oxaliplatin(IV) Prodrugs with Monohaloacetates.

What question did this study set out to answer?

To develop oxaliplatin(IV) prodrugs using monohaloacetates that enhance anticancer effects while minimizing side effects.

March 28, 2026Dalton Transactions0 citations

Engineering Oxaliplatin(IV) Prodrugs with Monohaloacetates for Redox-Responsive and Multimodal Anticancer Activity

FBFrancesca BinacchiUniversity of Pisa MPMartina PorcoUniversity of Pisa TFTiziana Funaioli

Key Result

The study reports the synthesis, characterization, and stability of novel oxaliplatin(IV) prodrugs engineered with monohaloacetates for anticancer activity.

Key Points

To develop oxaliplatin(IV) prodrugs using monohaloacetates that enhance anticancer effects while minimizing side effects.
Synthesis of oxaliplatin(IV) complexes with monohaloacetic acids.
Characterization of the chemical properties of the synthesized compounds.
Evaluation of cytotoxicity against cancer cell lines.
The new prodrugs exhibited increased antitumor activity compared to standard oxaliplatin.
Enhanced efficacy was observed under redox-responsive conditions.
Reduced side effects were reported in preliminary assessments.

Structured PICO

Intervention

Novel oxaliplatin(IV) complexes bearing monohaloacetic acids (MAAs)

Synthesis and characterization of novel oxaliplatin(IV) prodrugs designed for redox-responsive anticancer activity to address platinum-based chemotherapy limitations.

Abstract

A series of novel oxaliplatin(IV) complexes bearing monohaloacetic acids (MAAs) was synthesised to address the limitations of platinum-based chemotherapy related to severe side effects and resistance phenomena. Both symmetrical Pt(DACH)(ox)(MAA)₂...

AIに質問

Bookmark

View Full Paper

Cite This Study

Binacchi et al. (Thu,) conducted a other in Cancer (preclinical). Oxaliplatin(IV) Prodrugs with Monohaloacetates was evaluated. The study reports the synthesis, characterization, and stability of novel oxaliplatin(IV) prodrugs engineered with monohaloacetates for anticancer activity.

synapsesocial.com/papers/69c771198bbfbc51511e0fc2 https://doi.org/https://doi.org/10.1039/d6dt00471g

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper